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Two classes of viruses, namely members 
of the Potyviridae and Caliciviridae, use a novel 
mechanism for the initiation of protein 
synthesis that involves the interaction of 
translation initiation factors with a viral 
protein covalently linked to the viral RNA, 
known as VPg.  The calicivirus VPg proteins 
can interact directly with the initiation factors 
eIF4E and eIF3. Translation initiation on feline 
calicivirus (FCV) RNA requires eIF4E as it is 
inhibited by recombinant 4E-BP1. However, to 
date, there have been no functional studies 
carried out with respect to norovirus 
translation initiation, due to a lack of a suitable 
source of VPg-linked viral RNA. We have now 
used the recently identified murine norovirus 
(MNV) as a model system for norovirus 
translation and have extended our previous 
studies with FCV RNA to examine the role of 
the other eIF4F components in translation 
initiation. We now demonstrate that, as with 
FCV, MNV VPg interacts directly with eIF4E, 
although, unlike FCV RNA, translation of 
MNV RNA is not sensitive to 4E-BP1, eIF4E 
depletion or foot-and-mouth disease virus Lb 
protease-mediated cleavage of eIF4G. We also 
demonstrate that both FCV and MNV RNA 
translation require the RNA helicase 
component of the eIF4F complex, namely 
eIF4A, as translation was sensitive (albeit to 
different degrees) to a dominant negative form 
and to a small molecule inhibitor of eIF4A 
(hippuristanol). These results suggest that 
calicivirus RNAs differ with respect to their 
requirements for the components of the eIF4F 
translation initiation complex. 
 
Translation initiation on eukaryotic 
mRNAs is  a complex process and many 
translational control mechanisms are focused on 
the initiation stage  (1-3). The majority of host cell 
mRNAs are translated in a cap-dependent manner 
involving the recognition of their 5’ cap structure 
by the eIF4F initiation factor complex (4). eIF4F 
is known as the “cap-binding complex” and 
comprises three proteins: (1) eIF4E, the only 
factor with direct cap-binding activity, (ii) eIF4A, 
an RNA helicase and (iii) eIF4G which functions 
as a scaffold to bind several other factors such as 
eIF3, poly(A) binding protein (PABP), eIF4E and 
eIF4A. Subsequent to eIF4F binding to the 5’ cap, 
the 43S pre-initiation complex is recruited to the 
mRNA via its interaction with eIF3 (5). 
Positive-stranded RNA viruses have 
evolved a variety of mechanisms for subverting 
the host cell translation machinery for their own 
use (6,7). In many cases this results in the 
preferential translation of viral mRNAs, in the 
presence of relatively high concentrations of 
competing host cell mRNAs.  However, infection 
of cells by many picornaviruses also leads to the 
inhibition of host cell (cap-dependent) translation. 
This is primarily achieved through the cleavage of 
eIF4G, for example by the poliovirus 2A protease 
(8,9) or foot-and-mouth disease virus L protease 
(10), resulting in the separation of the eIF4A and 
eIF4E binding sites. Picornavirus mRNAs are still 
translated due to the presence of an internal 
ribosome entry site (IRES) element in the 5’ 
untranslated region that directs a cap-independent 
mechanism of translation. The C-terminal 
cleavage fragment of eIF4G is generally sufficient 
to support picornavirus IRES function (6).   
Caliciviruses are a major cause of viral 
gastroenteritis (GE) and have been associated with 
over 85% of non-bacterial GE outbreaks in Europe 
between 1995 and 2000 (11). The human 
caliciviruses, including the prototype Norwalk 
virus, have yet to be fully propagated in tissue 
culture, although recent results suggest that limited 
genome replication and encapsidation can occur 
using a vaccinia virus-driven expression system 
(12). In contrast to the human caliciviruses, feline 
calicivirus (FCV), porcine enteric calicivirus 
(PEC) (13,14) and murine norovirus 1 (MNV) (15) 
can be propagated in tissue culture. Reverse 
genetics systems also exist for both FCV (16) and 
PEC (17). Therefore FCV, PEC and MNV have 
been used as model systems to study calicivirus 
biology. 
We and others have previously reported 
that caliciviruses use a novel protein-directed 
translation initiation mechanism that involves the 
binding of translation initiation factors to the VPg 
protein that is covalently linked to the 5’ end of 
the viral RNA (18,19). This mechanism has not 
been demonstrated in any other animal RNA virus, 
but shares some similarity with a mechanism 
proposed for members of the plant potyvirus 
family (20-23). In our previous studies, we 
demonstrated that the VPg proteins of both FCV 
and Lordsdale virus (LDV), a human norovirus, 
interact directly with the eIF4E component of the 
eIF4F complex (19). Translation of FCV VPg-
linked mRNA was blocked by the eIF4E inhibitor 
protein, 4E-BP1, confirming a functional role for 
eIF4E and suggesting that the eIF4E:4G 
interaction is essential for FCV translation. Due to 
the lack of a suitable source of VPg-linked NV 
RNA, we were unable to extend this observation 
to norovirus translation. In the current study we 
have used the recently identified MNV (24) as a 
model for human norovirus translation. We have 
also extended our previous work on FCV to 
include the analysis of the other components of the 
eIF4F complex, namely eIF4G and eIF4A. We 
now demonstrate that the RNAs from caliciviruses 
differ in their functional requirements for the 
components of the eIF4F complex. Whereas each 
of the eIF4F factors are required for efficient 
translation of FCV mRNA, only eIF4A appears to 
play a critical role in MNV mRNA translation. 
 
Experimental Procedures 
Materials - FCV, strain Urbana was generated 
from the full-length infectious clone pQ14 (16) 
and propagated in Crandell-Rees feline kidney 
(CRFK) cells. MNV-1, strain CW.1, was the 
generous gift of Herbert Virgin (Washington 
University in St. Louis) and was propagated in the 
murine macrophage cell line RAW 264.7 as 
described (15). Antisera to LDV VPg was 
generated by immunisation of New Zealand White 
rabbits with recombinant VPg, purified as 
previously described (19). Antiserum to eIF4G 
was the kind gift of Simon Morley (University of 
Sussex). Antiserum to 4E-BP1 was purchased 
from Santa Cruz Biotechnology. Hippuristanol 
was isolated and used as described (25). 
 
Expression and Purification of Recombinant 
Proteins - FCV VPg was expressed and purified as 
previously described (19). The cDNA encoding 
MNV VPg was PCR amplified from a full-length 
clone of MNV kindly provided by Herbert Virgin 
(Washington University in St. Louis) using the 
primers IGRDG108 (5’ 
GCGCCGCGGTGGAGGAAAGAAGGGCAAG
AACAAGAAGGG-C) and IGRDG109 (5’ 
CGCGGATCCTTCTTCAGCAAA-GCTAAC) 
and cloned into pET26Ub after digestion with 
SacII and BamHI.  MNV VPg was purified from 
E. coli by affinity chromatography on NiCam 
agarose (Sigma), followed by an additional 
purification step on a heparin sepharose column 
(GE Healthcare). Recombinant 4E-BP1 was the 
generous gift of  Simon Morley (University of 
Sussex). The eIF4A dominant negative mutant, 
DQAD (26), was expressed and purified as 
described (27). Recombinant FMDV Lb protease 
was the generous gift of Tim Skern (University of 
Vienna). The eIF4E expression plasmid was the 
generous gift of Stephen Curry (Imperial College 
London). Histidine tagged eIF4E was purified by 
affinity chromatography on a Hitrap chelating 
column (GE Healthcare) followed by cap-
sepharose (GE Healthcare). eIF4E was eluted from 
the cap-sepharose column using a salt gradient to 
avoid  possible contamination with cap-analogue. 
 
Isolation of Calicivirus VPg-linked RNA from 
infected cells - FCV VPg-linked RNA was 
prepared from replication complexes isolated 4 
hours post infection using the Genelute 
purification system (Sigma) as previously 
described (19). MNV VPg-linked RNA was 
prepared from RAW 264.7 cells, infected at a 
multiplicity of infection of 2 TCID50 per cell, at 
18 h post infection, using the same system.  
 
Detection of VPg in MNV VPg-linked RNA 
preparations – RNA isolated from either mock or 
MNV infected cells was digested with RNAse 
cocktail (Ambion) for 1 hour at 37°C prior to 
analysis by western blotting with affinity purified 
anti-MNV VPg antiserum. 
 
In Vitro Translation Reactions - In vitro 
translation reactions were performed using the 
Flexi rabbit reticulocyte lysate system (Promega), 
using 25µg/ml, 50µg/ml and 12.5µg/ml of FCV, 
MNV and control in vitro transcribed RNAs 
respectively. These concentrations of RNA were 
previously determined to give a linear yield of 
translated product over the time course of the 
translation (90 minutes). In reactions that required 
the addition of either recombinant 4E-BP1, eIF4E 
or the dominant negative mutant (DQAD) form of 
eIF4A, reactions were pre-incubated with 
recombinant protein at 30°C for 15 minutes prior 
to the addition of RNA. After 90 minutes, 
reactions were terminated by the addition of SDS-
PAGE sample buffer and subsequently resolved on 
12.5% polyacrylamide gels. Pretreatment of RNA 
with proteinase K was carried out by incubation of 
RNA in 10mM Tris pH 8.0, 0.1mM EDTA, 
10µg/ml proteinase K for 30 minutes at 37°C 
followed by extraction with phenol:chloroform 
and precipitation with ethanol. MNV RNA was 
also treated as above but with the omission of 
proteinase K or the addition of EDTA-free 
protease inhibitor cocktail (Roche) as additional 
controls. Control in vitro transcribed RNA (of the 
form cap-CAT:IRES-Luc (28)) was treated in the 
same manner. In reactions that contained 
exogenous cap analogue, 50 or 500 µM cap 
analogue (m7G(5')ppp(5')G, Promega) was pre-
incubated with reticulocyte lysate at 30°C for 15 
minutes prior to the addition of RNA template. 
 
eIF4E depletion – eIF4E was depleted from RRL 
as previously described (29). Briefly, 4E-BP1 
(400nM) was incubated with RRL at 30°C for 10 
minutes prior to the addition of 0.5 volumes of 
cap-sepharose.  Bound complexes were removed 
by centrifugation and the depleted lysate aliquoted 
and frozen at -80°C until required. 
 
In Vitro Transcription - Capped dicistronic mRNA 
was prepared from XhoI linearised pGEM-
CAT:IRES-Luc (28) or pGEM-rLuc:IRES-fLuc, 
in which the CAT coding region was replaced with 
Renilla luciferase, using the Megascript 
transcription system (Ambion) in the presence of 
cap analogue (Promega). RNA was purified by 
lithium chloride precipitation and quantified by 
spectrophotometry. 
 
eIF4E Capture ELISA- Capture ELISAs to detect 
the interaction of eIF4E with VPg were performed 
essentially as described previously (22) except that 
murine eIF4E-GST or GST alone were purified 
using glutathione sepharose chromatography (GE 
Healthcare). The interaction of initiation factors 
with VPg was detected using an anti-GST 
monoclonal antibody.  
 
Cap-Sepharose Chromatography - Lysates from 
uninfected or infected RAW 264.7 cells, prepared 
18 hours post infection with MNV, were incubated 
with cap-sepharose (GE Healthcare) and eIF4E 
containing complexes isolated as previously 
described (30). Bound proteins were eluted with 
SDS-PAGE sample buffer and analysed by 
western blot. 
 
Virus Yield Assays- CRFK or RAW 264.7 cells 
were pre-treated with hippuristanol (125 nM to 
1µM) or DMSO as a control, for one hour prior to 
infection with FCV or MNV (MOI of 2).  
Infections were carried out in the presence of 
inhibitor/DMSO for 30 minutes at room 
temperature, after which virus and inhibitor were 
removed, and the cells washed with DMEM 
containing 10% FCS. Cells were then incubated in 
DMEM/10% FCS containing hippuristanol or 
DMSO at 37°C for 6 or 18 hours for FCV and 
MNV, respectively. After two freeze/thaw cycles, 
virus yield was determined by TCID50 on CRFK 
and RAW 264.7 cells for FCV and MNV, 
respectively. 
 
Cell Viability Assay -   The effect of 
hippuristanol on the viability of CRFK and RAW 
264.7 cells was examined using the CellTitre-Blue 
system (Promega) according to the manufacturer’s 
instructions. CRFK and RAW 264.7 cells were 
incubated with various concentrations of inhibitor 
or DMSO for 4 and 16 hours respectively. 
CellTitre-Blue reagent was then added to each 
well and incubation continued for a further 2 
hours, after which the level of fluorescence was 
determined according to manufacturer’s 
instructions. 
 
 
Results 
Murine norovirus RNA translation is insensitive to 
cap analogue - To date, the study of norovirus 
translation has been limited to in vitro binding 
analysis of the recombinant norovirus VPg with 
translation initiation factors (18). In order to fully 
evaluate the functional roles of initiation factors in 
norovirus translation, an in vitro translation system 
was required. MNV has previously been shown to 
replicate efficiently in the STAT1-negative murine 
macrophage cell line RAW 264.7 (15), hence this 
offered a potential source of norovirus VPg-linked 
RNA. The MNV VPg-linked RNA was prepared 
by extracting total RNA from RAW 264.7 cells at 
various times post infection. RNA prepared in a 
similar manner from FCV-infected cells was 
previously found to translate efficiently in the 
rabbit reticulocyte lysate system (19). Using 
similar in vitro translation conditions, RNA 
prepared from MNV infected cells also translated 
efficiently in rabbit reticulocyte lysates (Fig. 1A). 
The translation profile of the RNA isolated at 6h 
or 18 h post infection varied (Fig. 1A). Translation 
of a host cell mRNA present in uninfected 
extracts, highlighted in figure 1A with an asterisk, 
diminished during the course of infection, and was 
absent when RNA was prepared from cells 18 
hours post infection.  However, the synthesis of 
some virus encoded products (e.g. 32 kDa 
product) was greatly enhanced using the RNA 
isolated at 18h post infection compared to the 
RNA isolated at 6hrs. 
As we previously observed with FCV 
VPg-linked RNA, translation of MNV mRNA was 
found to require a protein covalently linked to the 
viral RNA (VPg), as pre-treatment of the RNA 
with proteinase K ablated translation (Fig. 1B). 
The inclusion of protease inhibitors in the reaction 
prevented the effect of proteinase K (Fig 1B).  In 
contrast, translation of in vitro synthesised, control 
capped dicistronic RNA was unaffected by 
proteinase K pre-treatment (Fig 1B). 
We and others have previously 
demonstrated that FCV translation was insensitive 
to the addition of exogenous cap analogue 
(m7G(5')ppp(5')G) (19,31). To determine if MNV 
mRNA translation also occurred in a cap 
analogue-insensitive manner, the effect of cap 
analogue on MNV mRNA in vitro translation was 
examined. Cap analogue had no significant effect 
on translation of MNV VPg-linked mRNA (Fig. 
1C). Cap-dependent translation from in vitro 
synthesised control dicistronic was inhibited, 
whereas cap-independent translation from the 
FMDV IRES was unaffected (Fig. 1D).   
Further evidence that the observed in vitro 
translation profile was the result of VPg-dependent 
translation was the observation that RNA prepared 
in this manner was found to be infectious after 
transfection into permissive cells but non-
infectious after treatment with proteinase K (data 
not shown).  
 
MNV VPg interacts with eIF4E - We have 
previously demonstrated a direct interaction of the 
FCV and LDV VPg proteins with eIF4E in vitro 
(19). This interaction was also observed in 
infected cells as FCV VPg could be isolated using 
a cap-sepharose affinity resin. To determine if a 
similar interaction existed between MNV VPg and 
eIF4E, recombinant MNV VPg was expressed and 
purified from E. coli (Fig. 2A). A capture ELISA, 
whereby VPg from both FCV and MNV were the 
immobilised ligand, was performed to study the 
interaction with eIF4E (Fig. 2B). Recombinant 
GST-murine eIF4E was retained by both MNV 
and FCV VPg, whereas a control protein, maltose 
binding protein (MBP), failed to bind detectable 
levels of eIF4E (Fig. 2B). GST alone did not bind 
to FCV VPg, MNV VPg or 4E-BP1 (Fig 2B). 
  To confirm that the MNV VPg protein 
also interacted with eIF4E during infection, eIF4E 
containing complexes were isolated from infected 
cells via cap-sepharose chromatography (Fig. 2C). 
Of the five forms of VPg generated during 
infection, all were retained on cap-sepharose, 
however the mature form and the ~32kDa 
precursor appear to be enriched (Fig. 2C). The 
levels of the eIF4F components present in cells or 
isolated by cap-sepharose chromatography were 
unaffected by infection (Fig 2C). Mature VPg, 
VPg precursors or eIF4F components were not 
isolated on control sepharose 4B alone (Fig. 2C). 
GAPDH was also not retained by cap-sepharose 
confirming the specificity of the assay (Fig 2C). 
 
Only the mature form of VPg is linked to viral 
RNA – Given our observation that all forms of 
VPg can be isolated by cap-sepharose 
chromatography, we wished to examine the form 
of VPg found covalently linked to viral RNA. 
RNA isolated from either mock or MNV infected 
cells was digested with RNAse and subsequently 
analysed by western blot. In agreement with 
previous findings with FCV (31), only the mature 
form of VPg was found to be covalently linked to 
MNV RNA (Fig 2D). 
 
Translation of MNV RNA is not inhibited by 4E-
BP1- Our previous analysis revealed that in vitro 
translation of VPg-linked FCV mRNA was 
sensitive to addition of the eIF4E repressor protein 
4E-BP1 (19). This protein binds to eIF4E and 
prevents the interaction with eIF4G (4). This data 
would therefore suggest that the eIF4E:4G 
interaction is required for FCV mRNA translation. 
To determine if a similar interaction is required for 
MNV mRNA translation, the effect of 
recombinant 4E-BP1 was examined (Fig 3A and 
3B). Whereas recombinant 4E-BP1 inhibited FCV 
and cap-dependent translation from a control 
dicistronic mRNA as expected, MNV mRNA 
translation and FMDV IRES-directed translation 
were unaffected (Fig. 3A and 3B). A protein 
translated from the MNV VPg-linked RNA 
preparations was also found to be sensitive to 4E-
BP1 addition (highlighted with an asterisk in Fig. 
3A). This is likely to represent a host cell mRNA 
that is translated in a cap-dependent manner and 
where visible, will be referred to as CPX. 
 
Depletion of eIF4E differentially affects 
calicivirus translation – To further determine if 
the MNV VPg-eIF4E interaction plays a 
significant role in MNV translation initiation, the 
translation of calicivirus RNA was examined in 
RRL depleted of eIF4E (Fig 3C). eIF4E was 
depleted as described (29) and the concomitant 
removal of eIF4G was prevented by the prior 
addition of 4E-BP1. The eIF4E:4E-BP1 was 
subsequently removed by cap-sepharose. Western 
blot analysis of depleted lysates demonstrated that 
whereas eIF4E levels were typically less than 10% 
of the levels seen in mock depleted lysates, the 
levels of the other eIF4F components, eIF4A and 
eIF4G, remained largely unaltered (Fig 3D). 
Analysis of the levels of recombinant 4E-BP1 
remaining in the depleted extract revealed that 
greater than 90% of the 4E-BP1 added to the 
reaction was removed during depletion (Fig 3D). 
Note that the rabbit polyclonal antiserum used to 
detect the recombinant 4E-BP1 did not detect the 
endogenous 4E-BP1 present in the RRL (Fig 3D).   
eIF4E depletion was found to specifically inhibit 
cap and FCV VPg-dependent translation, whereas 
FMDV IRES mediated translation was largely 
unaffected (Fig 3C).  The addition of recombinant 
His-tagged eIF4E to a final concentration of 
approximately 0.6µM restored cap and FCV VPg-
dependent translation to the levels found in mock 
depleted lysates (Fig 3C). eIF4E depletion reduced 
MNV VPg-dependent translation to between 55-
70% of the levels observed in mock depleted 
lysates (Fig 3C). However the addition of 
recombinant eIF4E to the depleted lysates did not 
restore MNV translation, suggesting that the 
observed effect was not due to the removal of 
eIF4E.  
 
 
FCV and MNV RNAs differ in their requirements 
for intact full-length eIF4G - eIF4G plays several 
critical roles in translation initiation and is 
recruited to the 5’ end of mRNA via it’s 
interaction with eIF4E (32). To confirm that the 
eIF4E:eIF4G interaction was not required for 
MNV translation, the eIF4E-interacting domain of 
eIF4G was separated from the C-terminus of 
eIF4G by cleavage with FMDV Lb protease and 
the effect on calicivirus translation analysed (Fig. 
4). Prior incubation of rabbit reticulocyte lysates 
with recombinant Lb protease led to a dose 
dependent cleavage of eIF4G (Fig. 4A). As 
expected, eIF4G cleavage resulted in inhibition of 
cap-dependent translation whereas FMDV IRES-
directed translation was unaffected (Fig. 4B and 
E). eIF4G cleavage resulted in inhibition of FCV 
mRNA translation, but resulted in  a slight 
stimulation of MNV translation (Fig. 4C,D and E) 
probably due to a decrease in competition from 
cellular mRNAs or release of eIF4G from the 
eIF4E:eIF4G complex. A protein translated from 
MNV RNA preparations, described above as CPX 
(highlighted with an asterisk in Fig 4D), was 
inhibited in reactions where eIF4G was cleaved 
with Lb protease (Fig 4D and 4E). 
 
Both MNV and FCV RNAs require eIF4A for 
translation initiation - A role for the remaining 
eIF4F component, namely the RNA helicase 
eIF4A, was initially examined by studying the 
effect of a recombinant dominant negative form of 
eIF4A on translation. The dominant negative 
mutant form of eIF4A containing a mutation in the 
ATPase B motif which changes the sequence 
DEAD to DQAD, herein referred to as eIF4ADQAD, 
results in inactivation of the ATPase and helicase 
activity (26). The eIF4ADQAD was found to inhibit 
cap-dependent translation as expected (Fig. 5A). 
As previously reported, translation from the 
porcine teschovirus (PTV-1) IRES was unaffected 
by this inhibitor (Fig. 5A) (27). MNV RNA 
translation was found to be highly sensitive to 
inhibition by eIF4ADQAD, with 1µg resulting in 
almost complete inhibition (Fig. 5C). FCV RNA 
translation was also sensitive to eIF4ADQAD, 
however higher concentrations were required to 
inhibit efficiently. Using 1µg of the inhibitor 
protein reduced FCV RNA translation by 
approximately 75% and even in the presence of 
2µg of eIF4ADQAD, translation still occurred (Fig. 
5B). 
 
A small molecule inhibitor of eIF4A, 
hippuristanol, inhibits translation of both FCV 
and MNV RNAs in vitro - To confirm that eIF4A 
was required for both MNV and FCV translation, 
the effect of a small molecule inhibitor of eIF4A 
function, hippuristanol, was examined. The 
inhibitor is a sterol isolated from the coral Isis 
hippuris and was identified via a high throughput 
screen for general translation inhibitors (25). 
Hippuristanol has been shown to function by 
binding to the C-terminal domain of eIF4A, 
inhibiting the RNA binding, ATPase activity and 
helicase activities of eIF4A(25). As expected, 
hippuristanol was found to inhibit cap-dependent 
translation in a dose dependent manner, whereas 
translation from the PTV-1 IRES was unaffected 
(Fig. 6A). Translation of both FCV and MNV 
mRNA was inhibited by hippuristanol, although to 
different levels (Fig. 6B, C and D). Complete 
inhibition of FCV RNA translation was observed 
at 1µM hippuristanol, whereas complete inhibition 
of MNV RNA translation was observed at the 
five-fold lower concentration of 0.2 µM. 
 
Hippuristanol inhibits FCV and MNV virus 
production - In addition to functioning as an 
efficient in vitro inhibitor of eIF4A function, 
hippuristanol has also been demonstrated to be cell 
permeable and efficiently inhibit eIF4A function 
in vivo (25). Hence, the effect of hippuristanol on 
the replication of both FCV and MNV was 
examined (Fig. 7A). As observed with the in vitro 
studies, MNV was found to be significantly more 
sensitive to hippuristanol than FCV. MNV virus 
yield was decreased by over 3000 fold at 250 nM 
hippuristanol, whereas FCV yield was unaffected 
(Fig. 7A). At 1µM hippuristanol the yield of FCV 
was reduced by over 170,000 fold.  Previous 
studies with hippuristanol have highlighted its 
cytotoxic nature, most likely due to inhibition of 
host cell cap-dependent translation (25). To 
control for the effects of hippuristanol on virus 
yield due to a significant decrease in cell viability, 
the cytotoxicity of hippuristanol was assayed. The 
viability of CRFK and RAW 264.7 cells was 
examined after exposure for 6 hours and 18 hours 
respectively (Fig. 7B). CRFK cells were largely 
unaffected by treatment with hippuristanol for 6 
hours, the time at which maximal virus yield is 
obtained from a single growth cycle of FCV (Fig 
7B). In contrast, exposure of RAW 264.7 cells to 
hippuristanol for 18 hours, the time required for 
maximal virus yield resulted in a marked decrease 
in cell viability at concentrations greater than 250 
nM (Fig. 7B). It is important to note, however, that 
at a hippuristanol concentration of 250nM, 90% of 
cells retained viability yet MNV yield was reduced 
by over 3000 fold (highlighted in Fig. 7), 
suggesting that this inhibitor specifically affects 
MNV production. 
 
 
Discussion 
Viruses have evolved a number of 
mechanisms for subverting the host cell translation 
machinery for their own use. In doing this, they 
often affect host protein synthesis using 
mechanisms which include the cleavage of 
initiation factors or the alteration of their 
phosphorylation status.  For example, during 
certain picornavirus infections (e.g. with 
poliovirus or FMDV) eIF4G is cleaved into N-
terminal and C-terminal fragments, separating the 
eIF4E-binding region from the eIF4A and eIF3-
binding sites (8-10). Alternatively, infection of 
cells with another picornavirus, 
encephalomyocarditis virus (EMCV) does not 
induce eIF4G cleavage but leads to 
dephosphorylation of 4E-BP1 which binds to 
eIF4E and prevents its interaction with eIF4G 
(33). Late in adenovirus infection, eIF4E itself is 
dephosphorylated as a result of the displacement 
of the eIF4E-kinase Mnk-1 from eIF4G (34). 
However, viruses have also evolved a number of 
ways in which to overcome these modifications to 
the host cell translational machinery.  For 
example, picornaviruses use a cap-independent 
mechanism of translation initiation which is 
dependent on an IRES within the 5’ UTR of the 
genome. The viral IRES elements can either bind 
the ribosome directly or recruit both canonical and 
non-canonical translation initiation factors to 
direct translation initiation, and can often function 
with the cleaved forms of initiation factors such as 
eIF4G (6). 
 Recent work has highlighted a novel 
translation initiation mechanism used by members 
of the Caliciviridae and Potyviridae families 
(18,19,23). This mechanism relies on the 
interaction of translation initiation factors with a 
protein (VPg) covalently linked to the 5’ end of 
the viral genome. These proteins are much larger 
(13-15 kDa) than the well characterised VPg 
proteins of picornaviruses (~23 amino acids) and 
share no sequence homology. It is important to 
note however, that whereas the interaction of 
potyvirus VPg with eIF4E competes with the cap 
binding activity of eIF4E (22), we have 
demonstrated that the interaction of calicivirus 
VPg with eIF4E can occur in the presence of cap 
((19) and current work). This may suggest that 
although these viruses have evolved similar 
strategies of VPg-dependent translation initiation, 
the VPg-eIF4E interaction may occur at different 
sites on eIF4E. 
During virus infection, several forms of 
calicivirus VPg are produced; these include the 
fully processed mature form and precursors where, 
in the case of FCV, VPg is linked to analogues of 
the picornavirus 3A and 3CD proteins. It is 
interesting to note that, as is the case for FCV 
where all forms of VPg can be isolated on cap-
sepharose (19), all forms of MNV VPg can also be 
found in complexes with eIF4E (Fig. 2C). 
However, the mature and ~32 kDa precursor form 
of MNV VPg appear to be enriched in eIF4E 
containing complexes (Fig 2C). The interaction of 
the potyvirus turnip mosaic virus VPg-containing 
precursors with eIF4E has also been observed 
(20). We have previously suggested that one 
function of the FCV VPg precursor-eIF4E 
interaction may be to increase the effective 
concentration of eIF4E within the replication 
complex (19). It is also possible that other 
initiation factors are recruited via specific 
interactions with precursor forms of VPg. It is 
noteworthy that PABP has been found to interact 
specifically with VPg-Pro from turnip mosaic 
virus (20). We have previously failed to observe 
an interaction between FCV VPg and PABP in 
vitro (19), however the interaction of PABP (and 
other factors) with MNV VPg-containing 
precursors has yet to be analysed.  
Our observation that MNV VPg interacts 
with eIF4E is not surprising given our previous 
observation with LDV VPg, as the two share 51% 
amino acid identity (data not shown). However, 
our results on the effect of adding 4E-BP1 or  
depletion of eIF4E on MNV RNA translation, at 
least in the rabbit reticulocyte lysate system, 
brings into question the functional relevance of 
this interaction for MNV translation. It is possible, 
but unlikely, that the MNV VPg-4E interaction is 
merely a remnant of an ancestral initiation 
mechanism, which is no longer required for 
efficient translation at least in vitro. A more 
attractive explanation is that the apparent role of 
the VPg-eIF4E interaction may be subtle, and 
possibly only observed under more native 
translation conditions within cells, where the input 
viral RNA concentration is very limited and has to 
compete with high concentrations of actively 
translating host cell mRNA. When a virus particle 
infects as host cell, the viral RNA would be 
present as a single copy and under these conditions 
it is easy to envisage how recruiting eIF4E to the 
5’ end of the viral RNA may stimulate MNV 
translation. It is possible that by recruiting eIF4E, 
other translation initiation factors such as eIF4G, 
eIF3 and PABP that may play a more significant 
role in MNV translation, would also be recruited. 
The fact that we do not observe any effect in the 
reticulocyte lysate system may also reflect the 
relatively high concentrations of initiation factors 
or the lack of compartmentalisation. Indeed a 
recent publication  has highlighted how the 
presence of high concentrations of endogenous 
capped mRNAs, as would be found during the 
initial stages of infection, can alter the relative 
contribution of initiation factors and affect the 
results obtained  from in vitro translation reactions 
(35). Further studies are currently under way to 
examine the effect that modification or depletion 
of eIF4E within cells has on calicivirus translation 
and replication.  
The initiation factor eIF4G plays several 
critical roles in translation initiation, but primarily 
functions as a ‘scaffold’ protein onto which other 
factors bind, ultimately resulting in the recruitment 
of the small ribosomal subunit and 43S pre-
initiation complex formation (36). Picornaviruses 
have evolved a mechanism to inhibit host cell cap-
dependent translation that is primarily determined 
by the cleavage of eIF4G by virus encoded 
proteases. Cleavage results in the separation of the 
eIF4E binding domain from the region that 
interacts with eIF4A and eIF3 (36), resulting in 
inhibition of cap-dependent translation. Our results 
demonstrate that, whereas FCV RNA translation 
requires intact eIF4G, MNV mRNA translation 
can occur when eIF4G is cleaved by FMDV Lb 
protease, suggesting the C-terminal fragment is 
sufficient or that the eIF4E:eIF4G interaction is 
not required (Fig. 4). Given that a direct 
interaction of norovirus VPg with eIF3 has been 
previously reported (18), one might then predict 
that eIF3 (and hence the C-terminal fragment of 
eIF4G which contains the eIF4A-binding sites) 
would still be recruited even when eIF4G is 
cleaved. Unlike our previous observations with 
FCV where eIF4G cleavage occurs at late stages 
of virus replication (37), eIF4G cleavage was not 
apparent during MNV infection (Fig 2C and 
unpublished observations). An interaction of MNV 
VPg with eIF3 has yet to be reported, but as noted 
above, the relatively high degree of sequence 
similarity with LDV VPg would make it a high 
possibility.  
eIF4A, the RNA helicase component of 
the eIF4F complex, is a member of the DEAD box 
family of putative ATPase/helicases (1). eIF4A is 
thought to cycle through the eIF4F complex 
during initiation (26,38,39), where its activity is 
stimulated by eIF4B and eIF4H (40,41). eIF4A is 
recruited to the 5’ end of mRNA molecules via an 
interaction with two binding sites within the 
middle and C-terminal regions of eIF4G (both in 
the C-terminal fragment generated by FMDV Lb) 
and results in an increase in the RNA-stimulated 
helicase activity of eIF4A (42). 
Hippuristanol (25), as well as pateamine 
(43,44) both affect eIF4A function, although 
through different mechanisms. Pateamine affects 
eIF4A function by deregulating the ATPase and 
helicase activities, stimulating both (43,44). 
Hippuristanol blocks eIF4A-dependent translation 
by inhibiting its RNA-binding, ATPase and 
helicase activities via interactions with the C-
terminal domain of eIF4A (25). Hippuristanol 
appears to be highly selective as it has no effect on 
other RNA and DNA helicases tested, and does 
not affect in vitro RNA splicing reactions (25). 
The relative requirement of a particular mRNA for 
eIF4A has been demonstrated to be at least 
partially determined by the level of RNA structure 
present in the 5’ end of the mRNA (39). However, 
it is important to note that the dependency of a 
particular mRNA on eIF4A is likely to be more 
complex than this, as previous work has shown 
that eIF4A can also enhance ribosome binding to 
unstructured mRNAs (32) including for example 
AMV-4, a capped viral transcript with little 
secondary structure (45). Given that our results 
demonstrate that translation initiation on MNV 
RNA shows a greater dependence on eIF4A 
function than FCV RNA, one might predict that 
the level of secondary structure is significantly 
greater in MNV RNA than FCV RNA. However, 
preliminary computational analysis of the RNA 
structure present at the 5’ end of the calicivirus 
genomes suggest that this is not the case (data not 
shown).  
Our current study indicates that 
caliciviruses differ in their functional requirements 
for translation initiation factors, a similar 
observation made with picornavirus IRES 
elements. For example, the EMCV IRES has a 
high requirement for eIF4A, whereas the PTV-1 
IRES shows similarity to the hepatitis C virus 
IRES in that it does not require any eIF4 initiation 
factors for function (28). The observation that a 
small molecule inhibitor of eIF4A inhibits 
calicivirus replication in cells, highlights how this 
novel paradigm of translation initiation may 
represent a good target for anti-viral intervention 
to control outbreaks of this economically 
important family of viruses. 
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Figure Legends
 
Figure 1. Murine norovirus RNA translation is not sensitive to cap analogue. 
Total RNA was prepared from either mock infected, M, or cells infected with MNV at a multiplicity of 
infection of 2 TCID50 per cell for 6 or 18 hours. RNA was purified, translated in rabbit reticulocyte 
lysates supplemented with [35S]-methionine and resolved by separation by 12.5% SDS-PAGE (A). An 
asterisk is used to highlight a product translated from an endogenous host cell mRNA, translation of 
which is diminished during infection. MNV RNA prepared 18 hours post infection or control dicistronic 
cap-Cat:FMDV IRES-Luc RNA was either mock treated (-Pk), treated with proteinase K (+Pk) or treated 
with proteinase K in the presence of protease inhibitors (+Pk +Inh) prior to in vitro translation (B). MNV 
(C) or control dicistronic cap-rLuc:FMDV IRES-fLuc RNA was translated in the presence of increasing 
concentrations of cap analogue and the effects on translation quantified by phosphorimaging (E). The 
mean of three experiments is shown with the error bars representing the maximum and minimum values. 
 
Figure 2. Murine norovirus VPg interacts with eIF4E in vitro and in vivo. 
Murine norovirus VPg was expressed and purified from E. coli as a C-terminal fusion to a 6 histidine tag 
(A). The interaction of murine eIF4E with either FCV or MNV VPg was assayed by capture ELISA. 
Wells were precoated with 10 µg of FCV or MNV VPg, maltose binding protein (MBP) or 4E-BP1 and 
incubated with 5 µg of GST-eIF4E or GST alone. Complexes were detected using anti-GST antibodies 
and the optical density at 420 nm quantified (B). Extracts from either mock infected (M) and MNV 
infected (MNV) cells were incubated with either sepharose 4B or cap-sepharose as described (30) and 
bound proteins analysed by  western blotting for both VPg, eIF4A, eIF4E, eIF4G and GAPDH (C). RNA 
isolated from mock (M) or MNV (MNV) infected cells was digested with RNAses and analysed for the 
presence of VPg by western blot (D).  
 
Figure 3. Murine norovirus RNA translation is not sensitive to 4E-BP1 or eIF4E depletion. 
Control dicistronic cap-rLuc:FMDV IRES-fLuc RNA, as well as FCV and MNV VPg-linked RNA were 
translated with or without prior incubation of the rabbit reticulocyte lysate with 36 µg/ml (final 
concentration) of  recombinant 4E-BP1 (A). The effect of recombinant 4E-BP1 on translation was 
quantified by phosphorimaging and expressed as a percentage of the untreated control (B). An 
endogenous host cell mRNA, present in MNV VPg-linked RNA preparations (highlighted with an 
asterisk in A), was inhibited by recombinant 4E-BP1 and was also quantified and designated CPX. The 
mean of three experiments is shown with the error bars representing the maximum and minimum values. 
FCV, MNV or control dicistronic cap-Cat:FMDV IRES-Luc RNA was translated in either mock or eIF4E 
depleted lysates, in the presence (+) or absence (-) of recombinant human eIF4E at a final concentration 
of 0.6 µM (C). eIF4E or mock depleted lysates were analysed by western blot for eIF4F components and 
4E-BP1 (D). 1µl of 0.6µM eIF4E-His or 400nM 4E-BP1-His were included as controls.  
 
Figure 4. Calicivirus RNAs differ in their requirements for intact eIF4G. 
Rabbit reticulocyte lysates were pre-incubated with or without recombinant FMDV Lb protease at a final 
concentration of 0.4 µg/ml, 0.08 µg/ml and 0.016 µg/ml. Samples of treated lysate were either western 
blotted with anti-eIF4G (A) or used to translate control dicistronic cap-rLuc:FMDV IRES-fLuc (B), FCV 
(C) or MNV VPg-linked RNA (D). The effects on translation were quantified by phosphorimaging and 
expressed as a percentage of the translation levels observed in mock treated control lysates (E). An 
endogenous host cell mRNA, present in MNV VPg-linked RNA preparations, highlighted with an asterisk 
in panel D, was inhibited by Lb protease cleavage of eIF4G and was also quantified (designated CPX). 
The mean of three experiments is shown with the error bars representing the maximum and minimum 
values. 
 
 
Figure 5. Calicivirus RNA translation in inhibited by an eIF4A dominant negative mutant. 
Rabbit reticulocyte lysates were pre-incubated with either 2µg of bovine serum albumin (BSA) or 
recombinant eIF4A dominant negative DQAD (2, 1, 0.5 or 0.25 µg of protein per reaction) and the effect 
on control dicistronic cap-CAT:PTV IRES-Luc (A), FCV (B) or MNV RNA (C) assayed. The levels of 
translation observed were quantified by phosphorimaging and expressed as a percentage of the BSA 
treated control lysate (D). The mean of three experiments is shown with the error bars representing the 
maximum and minimum values. 
 
 
Figure 6. In vitro translation of calicivirus RNA is inhibited by the eIF4A small molecule inhibitor 
hippuristanol.  
Rabbit reticulocyte lysates were pre-treated with either DMSO (-) or the eIF4A inhibitor hippuristanol at 
final concentrations of 1 µM, 0.2 µM and 0.04 µM. The effect of inhibitor on control bi-cistronic cap-
CAT:PTV1 IRES-Luc (A), FCV (B) or MNV RNA (C) was assayed and quantified by phosphorimaging 
(D). The mean of three experiments is shown with the error bars representing the maximum and minimum 
values. 
 
 
Figure 7. The eIF4A inhibitor hippuristanol inhibits production of both FCV and MNV. 
CRFK or RAW 264.7 cells were treated with either DMSO or increasing concentrations of hippuristanol 
for 1 hour prior to infection with either FCV or MNV respectively, at a multiplicity of infection of 2 
TCID50 per cell. After 6 hour in the case of FCV or 18 hours for MNV, samples were harvested and 
following two freeze-thaw cycles, the yield of infectious virus determined by TCID50 (A). CRFK or 
RAW 264.7 cells were treated with increasing concentrations of hippuristanol, in the absence of virus 
infection, for 6 or 18 hours respectively and the effect on cell viability assayed using the CellTitre-Blue 
system (Promega). Each concentration of hippuristanol was assayed in triplicate and the relative level of 
cell viability expressed as a percentage of DMSO treated cell control (B). The light grey column 
highlights the concentration at which viability of RAW 264.7 cells is largely unaffected, yet MNV virus 
yield is reduced by over 3000 fold. 
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